Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Ebola Outbreak in West Africa: Questions and Answers

CHART: Ebola Confirmed Cases & Deaths

Aug. 6 (Bloomberg) -- The outbreak of Ebola in Guinea, Liberia and Sierra Leone is the worst ever, killing more than 900 people this year. Below are frequently asked questions about the disease.

Q: How does an outbreak of Ebola start and spread? A: The origin of the virus is unknown, but fruit bats are considered the most likely host, according to the World Health Organization. Ebola jumps to humans from infected animals including chimpanzees, gorillas and bats that live in the rainforest, through contact with blood or other bodily fluids such as urine and saliva. Infection can also occur if broken skin or mucous membranes of a healthy person come into contact with items that have become contaminated with an Ebola patient’s infectious fluids such as soiled clothing, bed linen, or used needles.

Q: Can coughing and sneezing spread the virus? A: While an infected person who sneezes or coughs directly in another person’s face could infect that person, Ebola primarily enters the body through tiny cuts or abrasions, or through mucus membranes of the eyes, nose, ears and mouth.

Q: What are the symptoms of the virus? A: Sudden onset of fever, intense weakness, muscle pain, headache and sore throat are typical signs and symptoms. This is followed by vomiting, diarrhea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding. Infections can only be confirmed through laboratory testing.

Q: How is this outbreak different from past outbreaks? A: The current outbreak in Guinea, Sierra Leone and Liberia is the first time Ebola has appeared in West Africa. Until now, the Democratic Republic of Congo and Uganda have seen the biggest outbreaks, which have tended to be in isolated areas in single countries. A lack of border control has allowed infected people who didn’t seek medical attention because of fear, suspicion or stigma to travel freely between the three countries.

Q: How long does it take for symptoms to appear? A: In the past, the incubation period has ranged from 2 days to 21 days. In the current outbreak, it has been 4 days to 6 days, according to the WHO.

Q: What are the chances of the outbreak spreading beyond Africa? A: While Americans infected in Liberia have been transferred to a hospital in Atlanta, the U.S. Centers for Disease Control and Prevention has said an Ebola outbreak in the U.S. similar to the one in west Africa is highly unlikely because the U.S. has better infection controls in hospitals and in burial procedures.

Q: Is there any treatment or cure for Ebola? A: There is currently no specific treatment to cure the disease. Severely ill patients require intensive supportive care. They are frequently dehydrated and need intravenous fluids or oral rehydration with solutions that contain electrolytes.

Q: Where do we stand with developing drugs for Ebola? A: An experimental antibody cocktail being developed by the U.S. government, the Public Health Agency of Canada and two drug companies, Mapp Biopharmaceutical Inc. of San Diego and Toronto-based Defyrus Inc. has shown promise in animal tests. Called ZMapp, the drug, produced using tobacco plants, hasn’t been tested in humans, but was approved by the Food and Drug Administration for emergency use for two infected American health workers, and their conditions have improved. Safety trials in healthy humans may begin in the first half of next year, according to Defyrus. While Tekmira Pharmaceuticals Corp. is also testing its Ebola therapy, the FDA placed the trial on hold due to safety concerns.

To contact the reporter on this story: Makiko Kitamura in London at

To contact the editors responsible for this story: Phil Serafino at Robert Valpuesta, David Risser

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.